This knowledge is essential in part because of the possibility of transiently targeting p53 (e.g., by the use of small molecule modulators of p53) for selectively augmenting the sensitivity of tumor cells to such agents and hence improving the outcome of cancer therapy. This evidence concerns the gene TP53 and cancer.